Rubbert-Roth, Andrea http://orcid.org/0000-0002-9016-2833
Kato, Koji
Haraoui, Boulos
Rischmueller, Maureen
Liu, Yanxi
Khan, Nasser
Camp, Heidi S.
Xavier, Ricardo M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study
https://doi.org/10.1007/s40744-024-00694-x
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
Funding for this research was provided by:
AbbVie
Article History
Received: 21 February 2024
Accepted: 17 June 2024
First Online: 20 July 2024
Declarations
:
: Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Andrea Rubbert-Roth has received honoraria for lectures and consulting from AbbVie, Amgen, BMS, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, and Sanofi. Koji Kato is an employee of AbbVie and may hold stock or options. Boulos Haraoui has received speaker and/or consulting fees, and/or research grants, from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Maureen Rischmueller has received grant/research support from AbbVie, BMS, GSK, Janssen Global Services, Eli Lilly, Novartis, Servier, and UCB Biosciences, and consultant/speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Janssen Global Services, Novartis, and Pfizer. Yanxi Liu is an employee of AbbVie and may hold stock or options. Nasser Khan is a former employee of AbbVie and may hold stock or options. Heidi S. Camp is an employee of AbbVie and may hold stock or options. Ricardo M. Xavier has received research grants from AbbVie, Eli Lilly, Janssen, UCB and Pfizer, and consultant/speaker fees from AbbVie, Sandoz, Janssen, Novartis, Pfizer, and UCB.
: This study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. The trial protocol was approved by an independent ethics committee (IEC)/institutional review board (IRB) at each site per Good Clinical Practice (GCP). The list of study investigators for SELECT-CHOICE has been published previously []. All patients provided written informed consent prior to screening.